Kwang Suk Lee1, Kyo Chul Koo1, Byung Ha Chung2. 1. Department of Urology, Yonsei University College of Medicine, 211 Eonjuro, Gangnam-gu, Seoul, 135-720, Korea. 2. Department of Urology, Yonsei University College of Medicine, 211 Eonjuro, Gangnam-gu, Seoul, 135-720, Korea. chung646@yuhs.ac.
Abstract
PURPOSE: Reports on the impact of a family history of prostate cancer among Asians are scarce. We evaluated whether a positive prostate cancer family history is associated with the prognosis and features of the disease. METHODS: From January 2006 to December 2015, patients who received treatment for pathologically diagnosed prostate cancer were enrolled. Information on family history was obtained via self-administered questionnaires between January 2015 and December 2016. The overall survival rate for all patients and the rate of biochemical failure after radical prostatectomy were assessed according to the presence of family history. RESULTS: Of 1266 patients (median age, 68.1 years; median prostate-specific antigen, 8.73 ng/mL; median follow-up, 40.0 months), 47 (3.8%) were identified as having a family history. Men with a family history had a younger age, higher proportion of cases diagnosed before 55 years of age, and lower stage than those without a family history. Family history was not a potential risk factor for overall survival. In an analysis of patients who underwent radical prostatectomy (median prostate-specific antigen, 7.40 ng/mL; median follow-up, 40.5 months), no differences in pathologic characteristics were found between patients with (n = 39, 93.5%) and without (n = 567, 6.4%) a family history. Family history was not predictive of biochemical failure. CONCLUSIONS: A family history of prostate cancer seemed to have no effect on prognosis and disease aggressiveness. However, this study proposed a rationale for performing earlier prostate-specific antigen testing in men with a family history of prostate cancer.
PURPOSE: Reports on the impact of a family history of prostate cancer among Asians are scarce. We evaluated whether a positive prostate cancer family history is associated with the prognosis and features of the disease. METHODS: From January 2006 to December 2015, patients who received treatment for pathologically diagnosed prostate cancer were enrolled. Information on family history was obtained via self-administered questionnaires between January 2015 and December 2016. The overall survival rate for all patients and the rate of biochemical failure after radical prostatectomy were assessed according to the presence of family history. RESULTS: Of 1266 patients (median age, 68.1 years; median prostate-specific antigen, 8.73 ng/mL; median follow-up, 40.0 months), 47 (3.8%) were identified as having a family history. Men with a family history had a younger age, higher proportion of cases diagnosed before 55 years of age, and lower stage than those without a family history. Family history was not a potential risk factor for overall survival. In an analysis of patients who underwent radical prostatectomy (median prostate-specific antigen, 7.40 ng/mL; median follow-up, 40.5 months), no differences in pathologic characteristics were found between patients with (n = 39, 93.5%) and without (n = 567, 6.4%) a family history. Family history was not predictive of biochemical failure. CONCLUSIONS: A family history of prostate cancer seemed to have no effect on prognosis and disease aggressiveness. However, this study proposed a rationale for performing earlier prostate-specific antigen testing in men with a family history of prostate cancer.
Entities:
Keywords:
Positive family history; Prostatectomy; Prostatic neoplasm
Authors: Belinda F Morrison; William D Aiken; Richard Mayhew; Yulit Gordon; Folakemi T Odedina Journal: J Cancer Educ Date: 2017-06 Impact factor: 2.037
Authors: Lasse Saarimäki; Teuvo L Tammela; Liisa Määttänen; Kimmo Taari; Paula M Kujala; Jani Raitanen; Anssi Auvinen Journal: Int J Cancer Date: 2014-10-10 Impact factor: 7.396
Authors: P Lichtenstein; N V Holm; P K Verkasalo; A Iliadou; J Kaprio; M Koskenvuo; E Pukkala; A Skytthe; K Hemminki Journal: N Engl J Med Date: 2000-07-13 Impact factor: 91.245
Authors: A G Aprikian; M Bazinet; M Plante; A Meshref; C Trudel; S Aronson; M Nachabe; F Péloquin; J Déssureault; S Narod Journal: J Urol Date: 1995-08 Impact factor: 7.450
Authors: Marco Randazzo; Alexander Müller; Sigrid Carlsson; Daniel Eberli; Andreas Huber; Rainer Grobholz; Lukas Manka; Ashkan Mortezavi; Tullio Sulser; Franz Recker; Maciej Kwiatkowski Journal: BJU Int Date: 2015-10-06 Impact factor: 5.588
Authors: Stijn Roemeling; Monique J Roobol; Stijn H de Vries; Claartje Gosselaar; Theo H van der Kwast; Fritz H Schröder Journal: J Urol Date: 2006-04 Impact factor: 7.450
Authors: Andrew J Vickers; David Ulmert; Daniel D Sjoberg; Caroline J Bennette; Thomas Björk; Axel Gerdtsson; Jonas Manjer; Peter M Nilsson; Anders Dahlin; Anders Bjartell; Peter T Scardino; Hans Lilja Journal: BMJ Date: 2013-04-15